title: Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.
abstract: Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions (MPE).
  
  
  
  We searched the databases of MEDLINE, Web of Science, EMBASE, Goggle, Cochrance Library and CNKI to select the studies regarding the efficacy of Endostar to treat MPE. A total of 13 randomised controlled trials (RCTs) with 1066 patients were included.
  
  
  
  The overall response rate (ORR) (P < 0.001; odds ratio = 3.58) and disease control rate (DCR) (P < 0.001; odds ratio = 2.97) of Endostar combined with chemotherapeutic agents were significantly higher than those of chemotherapeutic agents alone. In addition, Endostar combined treatment remarkably promoted quality of life (QOL) of patients (P < 0.001; odds ratio = 3.04) compared with that of chemotherapeutic agents alone. Moreover, Endostar combined treatment did not have an impact on the incidence of adverse reactions (AEs) (P < 0.05).
  
  
  
  The efficacy of Endostar combined chemotherapeutic agents was superior to chemotherapeutic agents alone through thoracic perfusion in treating MPE, which indicated that Endostar could be an effective agent for controlling MPE.
authors.affiliation: Department of Respiratory Medicine, First Affiliated Hospital, Xi'an Medical University, 48 Fenghao West Road, Xi'an, 710077, China. research568rbx@yeah.net.
authors.forename: Rong
authors.initials: R
authors.lastname: Biaoxue
authors.affiliation: Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China.
authors.forename: Cai
authors.initials: C
authors.lastname: Xiguang
authors.affiliation: Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China.
authors.forename: Liu
authors.initials: L
authors.lastname: Hua
authors.affiliation: Department of Statistics and Epidemiology, Medical College, Lanzhou University, Lanzhou, China.
authors.forename: Gao
authors.initials: G
authors.lastname: Wenlong
authors.affiliation: Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Shuanying
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D043169:Endostatins / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D016017:Odds Ratio; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000473:pathology; D017594:Publication Bias; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D011994:Recombinant Proteins
keywords: Efficacy; Endostar; MPE; Malignant pleural effusions; Meta-analysis; Safety